A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

Real-world safety, tolerability, and effectiveness of abemaciclib in Chinese patients with HR+/HER2- EBC and ABC were consistent with clinical trials, with no new safety signals, supporting its positive real-world benefit-risk profile.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-01-19
DOI
https://doi.org/10.1093/oncolo/oyag013
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

Peng Yuan, Liu Yang, Lina Liu, Liqun Zou et al.
The Oncologist
Advanced Breast Cancer Therapies
article

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

Peng Yuan, Liu Yang, Lina Liu, Liqun Zou, Zhenxin Zhu, Suisheng Yang, Qiang Liu, Xuening Ji, Quchang Ouyang, Jinnan Li, Mopei Wang, Zhihua Li, Yuee Teng, Jianxia Liu, Ling Xu
article en

Abstract

Real-world safety, tolerability, and effectiveness of abemaciclib in Chinese patients with HR+/HER2- EBC and ABC were consistent with clinical trials, with no new safety signals, supporting its positive real-world benefit-risk profile.

The OncologistVol. 31(4)
Nanchang University (CN), Sun Yat-sen University (CN), Eli Lilly (United States) (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Sichuan University (CN), Soochow University (CN), National Cancer Center (US), West China Hospital of Sichuan University (CN), Sun Yat-sen Memorial Hospital (CN), Gansu Provincial Hospital (CN), Third Hospital of Nanchang (CN), Nanyang Institute of Technology (CN), Hunan Cancer Hospital (CN), Second Hospital of Nanchang (CN), Peking University First Hospital (CN), First Hospital of China Medical University (CN), Peking University Third Hospital (CN), Affiliated Zhongshan Hospital of Dalian University (CN), First Affiliated Hospital of Soochow University (CN), China Medical University (CN)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 77%
Advanced Breast Cancer Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China — Peng Yuan, Liu Yang, et al. · The Oncologist (2026) | TGRS Research Map | TGRS